The Biotechnology Industry Organization (BIO) today announces
preliminary programming for the 17th
Annual BIO CEO & Investor Conference to be held February 9-10,
2015 in New York City. The program
will include timely Fireside Chats with biotech luminaries, Business
Roundtables, in-depth Therapeutic Workshops and forward-looking Plenary
Sessions.
“With more than 1,800 partnering meetings expected and 150 companies
planning to present, the BIO CEO & Investor Conference serves a vital
role in bringing industry leaders together to form new partnerships and
collaborations which advance medical progress and innovation,” said BIO
President and CEO Jim Greenwood. “Investors are increasingly interested
in the biotech sector due to scientific breakthroughs, an improved
regulatory environment and strong earnings growth from large-cap
companies. The BIO CEO & Investor Conference offers them an ideal venue
to hear first-hand from leading biotech executives, fellow investors and
policymakers who will help drive the future of the industry.”
Fireside Chats include:
-
Ron Cohen, M.D., President & CEO, Acorda Therapeutics, Inc.
-
U.S. Rep. Diana DeGette, Energy and Commerce Committee,
Representative for the First District of Colorado
-
Peter Greenleaf, Chief Executive Officer, Sucampo
-
John Maraganore, Ph.D., CEO, Alynylam Pharmaceuticals
-
Ian C. Read, Chairman of the Board and CEO, Pfizer
-
U.S. Rep. Fred Upton*, Chairman of the Committee on Energy and
Commerce, Representative for the Sixth District of Michigan
*Invited
Business Roundtables include:
-
How Industry Rates Interactions with the FDA: What is working well
and what needs to improve?
Presentation of new BIO survey
data results on patterns in FDA reviews and approvals by product
division with a diverse panel to identify investment implications and
regulatory policy improvement opportunities.
-
Digital Health—Early Successes for Investors and Biotech R&D
Productivity
Perspectives from VCs and CVCs that have broad
exposure to digital health investments on which sub-segments they see
are getting market traction, especially where digital health companies
are improving R&D productivity for biotechs.
-
Emerging Trends in Deal Structures Post-IPO
Exploration of
innovative approaches to designing performance milestones and
structuring earnouts in M&A, plus the rising trend of swaps of
therapeutic assets to realign product portfolios.
Therapeutic Workshops include:
-
Getting Ahead of Ebola and Other Infectious Threats—Overturning
Assumptions
With rising support from governments and
philanthropies, hear how companies are advancing new platform
technologies, clinical trial designs, and partnership approaches that
can provide lessons on bringing new vaccines and therapies to market
faster, with implications likely for a wide array of diseases.
-
Personalizing Oncology Treatments with Molecular Diagnostics (ASCO
Preview)
As genetic analysis costs shrink significantly,
experts discuss enabling broader matching of patient-cancer-therapy,
lessons from the Cancer Genome Atlas, and the potential for
reevaluation of oncology clinical trial designs.
-
“Trust Your Gut”—Therapeutic Opportunities from the Microbiome
Review
of emerging data that the bacterial colonies of the digestive system
influence far more non-digestive systems than previously believed,
while creating natural antibiotics and other compounds that may be an
underleveraged source for efficient drug discovery.
Plenary Sessions include:
-
Following Venture Flow by Disease Indication—Past, Present and
Future Focus of VC Investment in Biotech
Summary of
exclusive, BIO analysis of 10 years of VC investments by therapeutic
area and degree of innovation; panel discussion of reasons behind the
trends and implications for investors.
-
Producing “21st Century Cures”—2015 U.S.
Legislative Outlook
In-depth look at emerging legislative
consensus from House Energy and Commerce committee with implications
for drug development and dramatically shortening time-to-market.
-
“What’s Liquidity Got to Do With It?”—2015 Market Outlook
Closing
panel discussion of the market momentum remaining after setting new
IPO records, while expectations of higher interest rates, pressure
from payers, tick-size debates, and other uncertainties suggest drags
on investors’ enthusiasm for biopharma stocks.
BIO is pleased to recognize the leadership provided by the BIO CEO &
Investor Conference sponsors including supporting banks BMO Capital
Markets, HC Wainwright & Co., JMP Securities, Lazard and ROTH Capital
Partners, LLC.
Media registration is complimentary for credentialed members of the
media. All registrations are subject to verification of credentials. To
complete your registration, visit here.
About BIO
BIO represents more than 1,100 biotechnology companies, academic
institutions, state biotechnology centers and related organizations
across the United States and in more than 30 other nations. BIO members
are involved in the research and development of innovative healthcare,
agricultural, industrial and environmental biotechnology products. BIO
also produces the BIO International Convention, the world’s largest
gathering of the biotechnology industry, along with industry-leading
investor and partnering meetings held around the world. BIO produces BIOtechNOW,
an online portal and monthly newsletter chronicling “innovations
transforming our world.” Subscribe
to BIOtechNOW.
Upcoming BIO Events
BIO
Pacific Rim Summit on Industrial Biotechnology & Bioenergy
December
7-9, 2014
San Diego, CA
BIO
CEO & Investor Conference
February 9-10, 2015
New York
City, NY
BIO-Europe
Spring
March 9-11, 2015
Paris, France
BIO
Asia International Conference
March 24-25, 2015
Tokyo,
Japan
BioEquity
Europe
May 19-20, 2015
Vienna, Austria
BIO
International Convention
June 15-18, 2015
Philadelphia, PA
Copyright Business Wire 2014